My NCBISign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 114

    1.

    The immunotherapy of Alzheimer's disease.

    Weksler ME.

    Immun Ageing. 2004 Nov 12;1(1):2.PMID: 15679923 [PubMed - as supplied by publisher]Related articlesFree article

    2.

    Novel approaches for immunotherapeutic intervention in Alzheimer's disease.

    Vasilevko V, Cribbs DH.

    Neurochem Int. 2006 Jul;49(2):113-26. Epub 2006 Jun 12. Review.PMID: 16765487 [PubMed - indexed for MEDLINE]Related articles

    3.

    Developing injectable immunoglobulins to treat cognitive impairment in Alzheimer's disease.

    Steinitz M.

    Expert Opin Biol Ther. 2008 May;8(5):633-42. Review.PMID: 18407766 [PubMed - indexed for MEDLINE]Related articles

    4.

    Anti-amyloid-beta immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials.

    Wilcock DM, Colton CA.

    J Alzheimers Dis. 2008 Dec;15(4):555-69. Review.PMID: 19096156 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Antibody responses, amyloid-beta peptide remnants and clinical effects of AN-1792 immunization in patients with AD in an interrupted trial.

    Kokjohn TA, Roher AE.

    CNS Neurol Disord Drug Targets. 2009 Apr;8(2):88-97. Review.PMID: 19355930 [PubMed - indexed for MEDLINE]Related articles

    6.

    Immunotherapy for Alzheimer's disease.

    Morgan D.

    J Alzheimers Dis. 2006;9(3 Suppl):425-32. Review.PMID: 16914881 [PubMed - indexed for MEDLINE]Related articles

    7.

    The immune system, amyloid-beta peptide, and Alzheimer's disease.

    Weksler ME, Gouras G, Relkin NR, Szabo P.

    Immunol Rev. 2005 Jun;205:244-56. Review.PMID: 15882358 [PubMed - indexed for MEDLINE]Related articles

    8.

    Immunological approaches for amyloid-beta clearance toward treatment for Alzheimer's disease.

    Solomon B.

    Rejuvenation Res. 2008 Apr;11(2):349-57. Review.PMID: 18341423 [PubMed - indexed for MEDLINE]Related articles

    9.

    Amyloid-beta Immunotherapy for Alzheimer's Disease.

    Fu HJ, Liu B, Frost JL, Lemere CA.

    CNS Neurol Disord Drug Targets. 2010 Mar 5. [Epub ahead of print]PMID: 20205640 [PubMed - as supplied by publisher]Related articles

    10.

    Targeting beta-amyloid pathology in Alzheimer's disease with Abeta immunotherapy.

    Nitsch RM, Hock C.

    Neurotherapeutics. 2008 Jul;5(3):415-20. Review.PMID: 18625453 [PubMed - indexed for MEDLINE]Related articles

    11.

    Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain.

    Boche D, Zotova E, Weller RO, Love S, Neal JW, Pickering RM, Wilkinson D, Holmes C, Nicoll JA.

    Brain. 2008 Dec;131(Pt 12):3299-310. Epub 2008 Oct 25.PMID: 18953056 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Immunotherapy for Alzheimer's disease and other dementias.

    Boche D, Nicoll JA, Weller RO.

    Curr Opin Neurol. 2005 Dec;18(6):720-5. Review.PMID: 16280685 [PubMed - indexed for MEDLINE]Related articles

    13.

    Beta-amyloidbased immunotherapy as a treatment of Alzheimers disease.

    Solomon B.

    Drugs Today (Barc). 2007 May;43(5):333-42. Review.PMID: 17724499 [PubMed - indexed for MEDLINE]Related articles

    14.

    Immunotherapy of Alzheimer's disease (AD): from murine models to anti-amyloid beta (Abeta) human monoclonal antibodies.

    Geylis V, Steinitz M.

    Autoimmun Rev. 2006 Jan;5(1):33-9. Epub 2005 Aug 1. Review.PMID: 16338209 [PubMed - indexed for MEDLINE]Related articles

    15.

    Immunotherapy against APP beta-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain abeta levels.

    Rakover I, Arbel M, Solomon B.

    Neurodegener Dis. 2007;4(5):392-402. Epub 2007 May 25.PMID: 17536186 [PubMed - indexed for MEDLINE]Related articles

    16.

    Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response.

    Maier M, Seabrook TJ, Lazo ND, Jiang L, Das P, Janus C, Lemere CA.

    J Neurosci. 2006 May 3;26(18):4717-28.PMID: 16672644 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Immunotherapy as treatment for Alzheimer's disease.

    Hawkes CA, McLaurin J.

    Expert Rev Neurother. 2007 Nov;7(11):1535-48. Review.PMID: 17997702 [PubMed - indexed for MEDLINE]Related articles

    18.

    CD40L disruption enhances Abeta vaccine-mediated reduction of cerebral amyloidosis while minimizing cerebral amyloid angiopathy and inflammation.

    Obregon D, Hou H, Bai Y, Nikolic WV, Mori T, Luo D, Zeng J, Ehrhart J, Fernandez F, Morgan D, Giunta B, Town T, Tan J.

    Neurobiol Dis. 2008 Feb;29(2):336-53. Epub 2007 Oct 16.PMID: 18055209 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Immunotherapy for Alzheimer's disease and other dementias.

    Boche D, Nicoll JA, Weller RO.

    Clin Neuropharmacol. 2006 Jan-Feb;29(1):22-7.PMID: 16518131 [PubMed]Related articles

    20.

    Developing novel immunogens for an effective, safe Alzheimer's disease vaccine.

    Maier M, Seabrook TJ, Lemere CA.

    Neurodegener Dis. 2005;2(5):267-72. Review.PMID: 16909008 [PubMed - indexed for MEDLINE]Related articles

    Display Settings:

    Format
    Items per page
    Sort by

    Send to:

    Choose Destination

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity

    You are here: NCBI > Literature > PubMed
    Write to the Help Desk